| Literature DB >> 28445008 |
Takashi Takahashi1, Tomohiro Fujita2,3, Akiyoshi Shibayama2,4, Yuzo Tsuyuki2,5, Haruno Yoshida2.
Abstract
BACKGROUND: Streptococcus dysgalactiae subsp. equisimilis (SDSE; a β-hemolytic streptococcus of human or animal origin) infections are emerging worldwide. We evaluated the clonal distribution of complement-mediated cell lysis-like gene (sicG) among SDSE isolates from three central prefectures of Japan.Entities:
Keywords: Clonal complex; Complement-mediated cell lysis-like gene; Japan; Random amplified polymorphic DNA analysis; Skin and soft tissue infections; Streptococcus dysgalactiae subsp. equisimilis; emm genotype
Mesh:
Substances:
Year: 2017 PMID: 28445008 PMCID: PMC5409013 DOI: 10.3343/alm.2017.37.4.297
Source DB: PubMed Journal: Ann Lab Med ISSN: 2234-3806 Impact factor: 3.464
Relationship between emm type and clonal complex number among Streptococcus dysgalactiae subsp. equisimilis strains collected
| Clonal complex (CC) number | |||||||
|---|---|---|---|---|---|---|---|
| CC17 | CC15 | CC29 | CC8 | CC25 | Singletons | Total N | |
| 18* | 18 | ||||||
| 6 | 2 (ST37/ST278†) | 8 | |||||
| 5 | 5 | ||||||
| 2 | 4 | 6 | |||||
| 4 | 4 | ||||||
| 2 | 2 | ||||||
| 1 | 1 | 2 | |||||
| 2 | 2 | ||||||
| 1 | 1 | ||||||
| 1 | 1 | ||||||
| 1 | 1 | ||||||
| 1 (ST26) | 1 | ||||||
| 1 (ST294*) | 1 | ||||||
| 1 | 1 | ||||||
| 1 (ST14*) | 1 | ||||||
| 1 (ST20) | 1 | ||||||
| Total N | 24 | 9 | 7 | 5 | 4 | 6 | 55 |
*There were Streptococcus dysgalactiae subsp. equisimilis isolates (n=3) from companion animals, and the ST294 was a novel one; †ST37 and ST278 were double locus variant.
Features of Streptococcus dysgalactiae subsp. equisimilis strains with streptococcal inhibitor of complement-mediated cell lysis-like gene and the hosts, Japan (2014–2016)
| No. of isolates with | Isolation year | Clinical specimen | Sequence type | Allelic profile | Antimicrobial agent resistance class [antimicrobial resistance gene] | Host (age/gender) | Living area in Japan (prefecture) | Clinical infections | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2014 | Blood | 17 | 4-4-1-2-17-6-2 | None | Human (85 y/F) | Saitama | Cellulitis | |
| 2 | 2014 | Blood | 205 | 4-4-1-2-17-44-2 | Tetracycline [ | Human (88 y/F) | Saitama | Cellulitis | |
| 3 | 2015 | Open pus | 17 | 4-4-1-2-17-6-2 | None | Human (76 y/M) | Saitama | Decubitus infection | |
| 4 | 2015 | Open pus | 17 | 4-4-1-2-17-6-2 | None | Human (3 m/F) | Saitama | Cellulitis | |
| 5 | 2015 | Blood | 17 | 4-4-1-2-17-6-2 | None | Human (80 y/M) | Saitama | Cellulitis | |
| 6 | 2015 | Open pus | 17 | 4-4-1-2-17-6-2 | None | Dog (Unknown/F) | Chiba | Pyoderma | |
| 7 | 2015 | Blood | 17 | 4-4-1-2-17-6-2 | None | Human (90 y/F) | Chiba | Bacteremia | |
| 8 | 2015 | Blood | 17 | 4-4-1-2-17-6-2 | None | Human (86 y/M) | Chiba | Bacteremia | |
| 9 | 2015 | Blood | 206 | 4-4-4-2-17-6-2 | None | Human (74 y/M) | Chiba | Bacteremia | |
| 10 | 2015 | Sputum | 205 | 4-4-1-2-17-44-2 | None | Human (60 y/M) | Tokyo | Aspiration pneumonia | |
| 11 | 2015 | Blood | 17 | 4-4-1-2-17-6-2 | None | Human (93 y/F) | Tokyo | Cellulitis | |
| 12 | 2015 | Open pus | 206 | 4-4-4-2-17-6-2 | None | Human (74 y/M) | Saitama | Decubitus infection | |
| 13 | 2015 | Sputum | 17 | 4-4-1-2-17-6-2 | Fluoroquinolone | Human (82 y/F) | Tokyo | Aspiration pneumonia | |
| 14 | 2016 | Throat swab | 17 | 4-4-1-2-17-6-2 | Fluoroquinolone | Human (72 y/M) | Tokyo | Pharyngitis | |
| 15 | 2016 | Blood | 205 | 4-4-1-2-17-44-2 | None | Human (84 y/M) | Chiba | Bacteremia | |
| 16 | 2016 | Blood | 17 | 4-4-1-2-17-6-2 | None | Human (82 y/F) | Tokyo | Cellulitis | |
| 17 | 2016 | Blood | 206 | 4-4-4-2-17-6-2 | None | Human (91 y/M) | Chiba | Bacteremia |
All the strains with sicG belonged to the carbohydrate group G and clonal complex 17.
Abbreviations: sicG, streptococcal inhibitor of complement-mediated cell lysis-like gene; y, years; m, months; M, male; F, female.
Sequence of all sicG amplicons was single pattern, and was similar to those of sicG in RE378 (AP011114.1, stG6792) (full length of sicG 486 bp, 100% homology) and TK01 (AB508817.1, stG2078) (485/486 bp, 99.8%).
Fig. 1Multi-alignments of isolate 6 (dog), isolate 14 (human), isolate 17 (human), strain RE378, and strain TK01. These alignments were generated with CLUSTAL W version 2.1 (latest version) (http://clustalw.ddbj.nig.ac.jp/).
Fig. 2Random amplified polymorphic DNA analysis of Streptococcus dysgalactiae subsp. equisimilis isolates with streptococcal inhibitor of complement-mediated cell lysis-like gene (sicG), using three different primers: H2, P5, and P6.
Abbreviations: M, marker; A, ATCC 12394.
Prevalence of Streptococcus dysgalactiae subsp. equisimilis strains with streptococcal inhibitor of complement-mediated cell lysis-like gene
| Isolation country (area) | Study period | N of screened isolates (N of isolates from sterile specimens) | N (%) of | N (%) of | N (%) of | Reference No. |
|---|---|---|---|---|---|---|
| Japan | 2000 to 2009 | 110 (51) | 19 (17.3) | 11 (57.9) | 0 | |
| Taiwan (central) | 2007 to 2011 | 246 (66) | 6 (2.4) | 1 (16.7) | 3 (50) | |
| Norway (western) | 2003 to 2009 | 129 (65) | 15 (11.6) | 8 (53.3) | 1 (6.7) | |
| Australia, US, Japan, Portugal, and India | Uncertain* | 193 (ND) | 30 (15.5) | ND | 0 | |
| Japan (central 3 prefectures) | 2014 to 2016 | 55 (25) | 17 (30.9) | 10 (58.8) | 14 (82.4) | This study |
*because of strain donation from multiple countries.
Abbreviations: sicG, streptococcal inhibitor of complement-mediated cell lysis-like gene; ND, not described.